
Abbott Labs (ABT) Stock Forecast & Price Target
Abbott Labs (ABT) Analyst Ratings
Bulls say
Abbott Laboratories is forecasting an organic sales growth range of 6.0-7.0% through 2025, supported by strong performances in its Electrophysiology and Structural Heart segments, which experienced organic growth rates of 13.7% and 11.3%, respectively. The company's Established Pharmaceuticals saw a 7.1% organic increase in sales, with strong contributions from key emerging markets, highlighting its broad international footprint where approximately 60% of sales are derived. Furthermore, Abbott's commitment to dividend growth, having increased payouts for over 50 consecutive years, coupled with a robust balance sheet and the potential for strategic mergers and acquisitions, reinforces a favorable outlook for the company's long-term financial stability and growth.
Bears say
Abbott Laboratories faces a negative outlook primarily due to the significant decline in Covid-19 testing sales, dropping from $265 million in Q3'24 to $69 million in Q3'25, which has led the company to adjust its financial outlook accordingly. Additionally, the company is experiencing broader macroeconomic pressures such as inflation and foreign exchange fluctuations, further complicating its revenue projections. The continuing struggles in its Diagnostics segment, particularly in China and the impact of funding cuts for HIV tests, signal persistent operational challenges that may hinder revenue growth moving forward.
This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.
Abbott Labs (ABT) Analyst Forecast & Price Prediction
Start investing in Abbott Labs (ABT)
Order type
Buy in
Order amount
Est. shares
0 shares